Metastatic Cutaneous Squamous Cell Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major metastatic cutaneous squamous cell cancer markets are expected to exhibit a CAGR of 5.64% during 2024-2034.
The metastatic cutaneous squamous cell cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Cutaneous Squamous Cell Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic cutaneous squamous cell cancer is an aggressive form of skin tumor that arises from the squamous cells in the outermost membrane of the skin. While this condition typically begins as a localized skin lesion, it becomes metastatic when cancerous cells spread to numerous other parts of the body through the lymphatic system or bloodstream. The symptoms of the ailment can vary but often include the development of nodules or masses in the skin, which may be painful, bleeding, or ulcerated. These lesions can appear on sun-exposed areas or regions with a history of chronic inflammation or prior skin damage. In advanced stages, patients might experience weight loss, fatigue, and a decline in overall health. The diagnosis of metastatic cutaneous squamous cell cancer involves a combination of clinical evaluation, physical testing, and a biopsy of the affected skin or lymph nodes. The pathological examination of the biopsy also helps to confirm the diagnosis and assess the aggressiveness of the cancer.
The escalating prevalence of mutations in the TP53 and CDKN2A genes, which result in uncontrolled cell growth in the skin, particularly affecting the epidermal layer, is primarily driving the metastatic cutaneous squamous cell cancer market. In addition to this, the inflating utilization of advanced therapeutic interventions, including immune checkpoint inhibitors, targeted therapies, and surgical excisions, aimed at effectively managing the disease and impeding its further progression, is creating a positive outlook for the market. Moreover, the widespread adoption of comprehensive diagnostic techniques, such as molecular profiling and imaging modalities, to accurately detect and assess the extent of metastasis is also bolstering the market growth. Apart from this, the rising usage of supportive care measures, encompassing pain management, wound care, and psychological support, since they help to enhance the overall quality of life for patients and alleviate the indications of the disease, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy, on account of its numerous advantages, like eradicating tumor cells, ensuring clear margins, and preserving the function and appearance of the skin, is also augmenting the market growth. Furthermore, the increasing demand for photodynamic procedures to selectively destroy cancerous cells is expected to drive the metastatic cutaneous squamous cell cancer market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the metastatic cutaneous squamous cell cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic cutaneous squamous cell cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic cutaneous squamous cell cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the metastatic cutaneous squamous cell cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the metastatic cutaneous squamous cell cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current metastatic cutaneous squamous cell cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the metastatic cutaneous squamous cell cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic cutaneous squamous cell cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic cutaneous squamous cell cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with metastatic cutaneous squamous cell cancer across the seven major markets?
What is the size of the metastatic cutaneous squamous cell cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic cutaneous squamous cell cancer?
What will be the growth rate of patients across the seven major markets?
Metastatic Cutaneous Squamous Cell Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for metastatic cutaneous squamous cell cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic cutaneous squamous cell cancer market?
What are the key regulatory events related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by status related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by phase related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by route of administration related to the metastatic cutaneous squamous cell cancer market?
The metastatic cutaneous squamous cell cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic Cutaneous Squamous Cell Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic cutaneous squamous cell cancer is an aggressive form of skin tumor that arises from the squamous cells in the outermost membrane of the skin. While this condition typically begins as a localized skin lesion, it becomes metastatic when cancerous cells spread to numerous other parts of the body through the lymphatic system or bloodstream. The symptoms of the ailment can vary but often include the development of nodules or masses in the skin, which may be painful, bleeding, or ulcerated. These lesions can appear on sun-exposed areas or regions with a history of chronic inflammation or prior skin damage. In advanced stages, patients might experience weight loss, fatigue, and a decline in overall health. The diagnosis of metastatic cutaneous squamous cell cancer involves a combination of clinical evaluation, physical testing, and a biopsy of the affected skin or lymph nodes. The pathological examination of the biopsy also helps to confirm the diagnosis and assess the aggressiveness of the cancer.
The escalating prevalence of mutations in the TP53 and CDKN2A genes, which result in uncontrolled cell growth in the skin, particularly affecting the epidermal layer, is primarily driving the metastatic cutaneous squamous cell cancer market. In addition to this, the inflating utilization of advanced therapeutic interventions, including immune checkpoint inhibitors, targeted therapies, and surgical excisions, aimed at effectively managing the disease and impeding its further progression, is creating a positive outlook for the market. Moreover, the widespread adoption of comprehensive diagnostic techniques, such as molecular profiling and imaging modalities, to accurately detect and assess the extent of metastasis is also bolstering the market growth. Apart from this, the rising usage of supportive care measures, encompassing pain management, wound care, and psychological support, since they help to enhance the overall quality of life for patients and alleviate the indications of the disease, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of radiation therapy, on account of its numerous advantages, like eradicating tumor cells, ensuring clear margins, and preserving the function and appearance of the skin, is also augmenting the market growth. Furthermore, the increasing demand for photodynamic procedures to selectively destroy cancerous cells is expected to drive the metastatic cutaneous squamous cell cancer market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the metastatic cutaneous squamous cell cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic cutaneous squamous cell cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic cutaneous squamous cell cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the metastatic cutaneous squamous cell cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the metastatic cutaneous squamous cell cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current metastatic cutaneous squamous cell cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the metastatic cutaneous squamous cell cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the metastatic cutaneous squamous cell cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the metastatic cutaneous squamous cell cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of metastatic cutaneous squamous cell cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with metastatic cutaneous squamous cell cancer across the seven major markets?
What is the size of the metastatic cutaneous squamous cell cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of metastatic cutaneous squamous cell cancer?
What will be the growth rate of patients across the seven major markets?
Metastatic Cutaneous Squamous Cell Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for metastatic cutaneous squamous cell cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic cutaneous squamous cell cancer market?
What are the key regulatory events related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by status related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by phase related to the metastatic cutaneous squamous cell cancer market?
What is the structure of clinical trial landscape by route of administration related to the metastatic cutaneous squamous cell cancer market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - UNMET NEEDS
10 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - KEY ENDPOINTS OF TREATMENT
11 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - MARKETED PRODUCTS
11.1 List of Metastatic Cutaneous Squamous Cell Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Libtayo (Cemiplimab-Rwlc) - Regeneron Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda(Pembrolizumab) - Merck and Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - PIPELINE DRUGS
12.1 List of Metastatic Cutaneous Squamous Cell Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 IFX-1- InflaRx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. METASTATIC CUTANEOUS SQUAMOUS CELL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
16 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - UNMET NEEDS
10 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - KEY ENDPOINTS OF TREATMENT
11 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - MARKETED PRODUCTS
11.1 List of Metastatic Cutaneous Squamous Cell Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Libtayo (Cemiplimab-Rwlc) - Regeneron Pharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Keytruda(Pembrolizumab) - Merck and Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - PIPELINE DRUGS
12.1 List of Metastatic Cutaneous Squamous Cell Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 IFX-1- InflaRx
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. METASTATIC CUTANEOUS SQUAMOUS CELL CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Metastatic Cutaneous Squamous Cell Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Metastatic Cutaneous Squamous Cell Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Metastatic Cutaneous Squamous Cell Cancer - Access and Reimbursement Overview
16 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 METASTATIC CUTANEOUS SQUAMOUS CELL CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
